News
Latest Updates from Lophora
Lophora Submits Clinical Trial Authorisation (CTA) Application to the French
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat...
Read More
Structure-Activity Relationships of Lophora’s selective serotonin 5-HT2A receptor agonists published in
The Lophora team has published a paper detailing the discovery and structure of the lead...
Read More
Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and
Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark,...
Read More
Lophora completes preclinical development of LPH-5 for treatment-resistant depression
Lophora has completed the pre-clinical development of its first-in-class lead candidate LPH-5 for Treatment Resistant...
Read More
Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5
Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation...
Read More
Lophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression
Lophora has been granted a $1.5M convertible loan by the Novo Nordisk Foundation to advance...
Read MoreRecent Media Highlights on Lophora
Companies attract venture funding for redesigned psychedelic drugs
CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 in the landscape of...
Read More
Lophora submits CTA Application for LPH-5 directed towards a Phase
Lophora interviewed by Medwatch (in Danish) https://medwatch.dk/Medicinal___Biotek/article17157459.ece
Read More
Next-generation psychedelics: should new agents skip the trip?
CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 inthe landscape of next...
Read More